Beta Thalassemia Market Size in the 7MM is expected to grow by 2032 | DelveInsight

Beta Thalassemia Market

DELHI, DELHI, INDIA, July 5, 2024 /EINPresswire.com/ -- DelveInsight's 'Beta Thalassemia Market Insights, Epidemiology, and Market Forecast—2032' report deliver an in-depth understanding of Beta Thalassemia, historical and forecasted epidemiology as well as the market trends in the United States and EU5 (Germany, Spain, Italy, France, and United Kingdom).

Beta Thalassemia Market Insights

Key Takeaways from the Beta Thalassemia Market Report

• The increase in Beta Thalassemia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.

• As per DelveInsight analysis, the Beta Thalassemia market is anticipated to witness growth at a considerable CAGR.

• The leading Beta Thalassemia Companies working in the market include Novartis, Merck, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, SILENCE Therapeutics, and others.

• Promising Beta Thalassemia Pipeline Therapies in the various stages of development include SP-420, VIT-2763 once a day (QD), BRL-101, CS-101, and others.

• April 2024: Celgene announced a study of Phase 2 clinical trials for ACE-536. This is a Phase 2a study to evaluate the safety and pharmacokinetics (PK) of luspatercept in pediatric participants with β-thalassemia.

• April 2024: Agios Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Mitapivat. The primary purpose of this study is to compare the effect of mitapivat versus placebo on transfusion burden in participants with transfusion-dependent alpha- or beta-thalassemia (TDT).

• April 2024: Vertex Pharmaceuticals announced a study of Phase 3 clinical trials for CTX001. This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).

Discover which therapies are expected to grab the Beta Thalassemia Market Share @ Beta Thalassemia Market Outlook

Beta Thalassemia Overview
Beta thalassemia (β-thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobinsubunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheralblood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobinanalysis.

Beta Thalassemia Epidemiology Segmentation Insights
The epidemiology section of Beta Thalassemia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

- Total Beta Thalassemia Prevalent Cases
- Beta Thalassemia Type-specific Diagnosed Prevalent Cases
- Beta Thalassemia Diagnosed Prevalent Cases
- Beta Thalassemia Treatable Cases

Download the report to understand which factors are driving Beta Thalassemia Epidemiology trends @ Beta Thalassemia Prevalence

Beta Thalassemia Market Insights
To counter unmet market needs and provide better treatment choices for beta thalassemia, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.

Beta Thalassemia Market Dynamics
The Beta Thalassemia market is anticipated to be driven in the coming years owing to the launch of emerging therapies therapies and improvement in the research and development activities.

The participation of the key players such as Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, and others will bring a change in the market dynamics during the forecast period (2023–2032)

Beta Thalassemia Drugs Uptake

• PYRUKYND (mitapivat), developed by Agios Pharmaceuticals, is an oral, smallmolecule, allosteric activator of the RBC-specific form of pyruvate kinase (PK-R). It is the first FDA-approved disease-modifying therapy for pyruvate kinase deficiency. Pyruvate kinase-R is a key enzyme for maintaining energy homeostasis in RBCs. In healthy adults, mitapivat activates wild-type pyruvate kinase-R and increases ATP levels in RBCs. Currently, the company is evaluating mitapivat in two Phase III ENERGIZE and ENERGIZE-T (NCT04770753 and NCT04770779) studies in adults with non-transfusiondependent and transfusion-dependent α- or β-thalassemia, respectively.

• Exagamglogene autotemcel (exa-cel), formerly known as CTX001, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy which aims to edit a person's hematopoietic stem cells to produce fetal hemoglobin (hemoglobin F). Vertex Pharmaceuticals is collaborating with CRISPR Therapeutics to investigate the use of a gene-editing technology, known as CRISPR/Cas9, to discover and develop a potential one-time treatment for transfusion-dependent beta thalassemia. HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth, which then switches to the adult form of hemoglobin. In June 2023, FDA accepted the BLA of exagamglogene autotemcel (exa-cel) for transfusion-dependent beta thalassemia (TDT). The PDUFA target action date for TDT is March 30, 2024. The company is currently conducting trials in Phase III (NCT05356195, NCT05477563) and Phase II/III (NCT03655678) to evaluate CTX001 in adults and pediatric patients with transfusiondependent β-Thalassemia.

• SP-420 belongs to a novel class of orally active iron chelators called desferrithiocins. The drug has the ability to cross the blood-retinal and blood-brain barriers, requisite for retinal and neurological indications. In November 2021, Pharmacosmos acquired AbFero Pharmaceuticals and continued with the development of SP-420 in order to bring new treatment options for patients suffering from transfusional iron overload and other iron mediated. Recently, in September 2023, Pharmacosmos has initiated a Phase II trial (NCT05693909) of SP-420 in patients with transfusion-dependent β-thalassemia.

• EDIT-301, developed by Editas Medicine, is an experimental gene editing medicine that consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters. Red blood cells derived fromEDIT-301 CD34+ cells demonstrate a sustained increase in fetal hemoglobin production, which has the potential to provide a one-time, durable treatment benefit for people living with severe SCD and TDT. Currently, the drug is being studied in a Phase I/II trial (NCT05444894) in adult participants with transfusion dependent beta thalassemia.

To know more about Beta Thalassemia treatment guidelines, visit @ New Beta Thalassemia Drugs

Beta Thalassemia Market Outlook
The report's outlook on the Beta Thalassemia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Beta Thalassemia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Beta Thalassemia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Beta Thalassemia market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Beta Thalassemia Companies
Several companies working in the market include Novartis, Merck, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, SILENCE Therapeutics, and others.

Learn more about the FDA-approved drugs for Beta Thalassemia @ Drugs for Beta Thalassemia Treatment- https://www.delveinsight.com/sample-request/beta-thalassemia-market-forecast?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Beta Thalassemia Market Report
- Coverage- 7MM
- Study Period- 2019-2032
- Beta Thalassemia Companies- Novartis, Merck, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, SILENCE Therapeutics, and others
- Beta Thalassemia Pipeline Therapies- SP-420, VIT-2763 once a day (QD), BRL-101, CS-101, and others.
- Beta Thalassemia Market Dynamics: Beta Thalassemia Market Drivers and Barriers
- Beta Thalassemia Market Access and Reimbursement, Unmet Needs, KOL's Views, and Analyst's Views

Discover more about Beta Thalassemia Drugs in development @ Beta Thalassemia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/beta-thalassemia-market-forecast?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

in today's world. Please see our Editorial Guidelines for more information.